Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers
On January 13, 2022, the board of directors of H-Cyte, Inc. (the "Company")
appointed Richard Rosenblum and Matthew Anderer as new directors of the Company,
effective January 17, 2022.
Mr. Rosenblum (62) is a business veteran and entrepreneur in the areas of the
financial services, capital markets, healthcare, technology and real estate. His
experience ranges from serving as managing director at several investment
merchant banks to heading companies as a C-suite executive. He also sits on the
boards of public and private healthcare, life sciences and technology-sector
companies.
Mr. Rosenblum is currently President, CFO and Board Member of Innovative Payment
Solutions, Inc., a California-based FinTech company focused on building a 21st
century universal digital payment and money remittance platform. As the founder
of Harborview Capital Advisors, LLC, Mr. Rosenblum leads a team of strategic
advisors in the areas of capital formation, merchant banking and management
consulting, and has raised more than $250 million in capital funding for
companies. Since founding it over 20 years ago, Mr. Rosenblum has served as
manager and director of Harborview Property Management LLC, raising over $100
million while managing domestic and international commercial and multi-family
real estate assets. From 2008 to 2014, Mr. Rosenblum was Director, President and
Executive Chairman of Alliqua Biomedical Inc. (NASDAQ: ALQA), a leader in
hydrogel manufacturing technology in the wound care sector.
Mr. Rosenblum received his B.A. in Finance & Accounting from the State
University of New York at Buffalo in 1981, graduating summa cum laude.
Mr. Rosenblum will receive $5,000 a month as compensation from the Company for
his service as a director.
Mr. Anderer (55) started his career in the United States Air Force as a fast jet
and special operations pilot and instructor before taking operational and staff
officer roles with Special Operations Command and NATO. He has commanded
worldwide airlift capability of the highest posts within the White House and
from a technology perspective, he has directed a range of high-profile,
high-value acquisition projects. Mr. Anderer was the Director of the US Air
Force leadership and citizenship development program for 220,000 cadets before
taking command of the busiest air mobility group in the world, responsible for
support to destinations world-wide. Among other contingency crisis operations in
this capacity, Matt played a crucial role establishing robust, resilient, and
repeatable processes to prevent the potential spread of the Ebola Virus for
aircraft, cargo and passengers that transited sub-Saharan West Africa. He is
currently the training systems Country Integration Lead for Lockheed Martin's
F-35 International customers, a position that he has held since prior to 2017.
Most recently, Mr. Anderer was also a member of the Board for Deverra
Theraputics, a clinical stage cell therapy company headquartered in Seattle. He
is a graduate of Villanova University, Air Command and Staff College, Naval
Staff College and the Geneva Center for Security Policy.
Mr. Anderer will receive $5,000 a month as compensation from the Company for his
service as a director.
The board of directors of the Company has affirmatively determined that both Mr.
Rosenblum and Mr. Anderer meet the applicable standards for independent
directors under Rule 10A-3 of the Securities Exchange Act of 1934.
There is no arrangement or understanding between either Mr. Rosenblum or Mr.
Anderer and any other persons pursuant to which either Mr. Rosenblum or Mr.
Anderer was elected as a director of the Company. There are no family
relationships between either Mr. Rosenblum or Mr. Anderer and any of the
Company's officers or directors. Other than as described herein, there are no
other transactions to which the Company or any of its subsidiaries is a party in
which either Mr. Rosenblum or Mr. Anderer has a material interest subject to
disclosure under Item 404(a) of Regulation S-K.
© Edgar Online, source Glimpses